Closing The Scale-Up Gap: N-1 Perfusion Strategies For Commercial-Ready Biologics

Biologics production often hits a snag when scaling up from development to commercial manufacturing. The "scale-up gap" appears when traditional methods, like old-school seed trains and limited facility space, can't keep up with higher production volumes. This can lead to delays, failed batches, and tough choices between speed and adaptability.

In this webinar, Boehringer Ingelheim BioXcellence™ introduces a solution: modular N-1 perfusion strategies. By integrating this method into current fed-batch platforms, companies can overcome these limitations. The approach is designed to shorten timelines for preparing the cell culture, ease the burden on facilities, and create a more efficient and reliable process for large-scale manufacturing.

What You'll Learn

• Solve Scale-Up Problems: Discover common hurdles in biologics manufacturing and how N-1 perfusion helps solve them.
• Boost Speed and Reliability: Understand how this modular approach can accelerate seed train timelines and improve overall process dependability.
• Prepare for Implementation: Learn the key factors for fitting perfusion strategies into existing facilities and transferring the technology successfully to a commercial scale.